| __timestamp | MannKind Corporation | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 4042025 |
| Thursday, January 1, 2015 | 108402000 | 5279557 |
| Friday, January 1, 2016 | 46928000 | 8073913 |
| Sunday, January 1, 2017 | 74959000 | 44864073 |
| Monday, January 1, 2018 | 79716000 | 53488904 |
| Tuesday, January 1, 2019 | 74669000 | 65896361 |
| Wednesday, January 1, 2020 | 59040000 | 69968267 |
| Friday, January 1, 2021 | 77417000 | 92047281 |
| Saturday, January 1, 2022 | 91473000 | 131819000 |
| Sunday, January 1, 2023 | 94314000 | 87501000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two notable players: MannKind Corporation and Pharming Group N.V., from 2014 to 2023. Over this period, MannKind Corporation consistently maintained higher SG&A expenses, peaking in 2015 with a 38% increase from the previous year. Meanwhile, Pharming Group N.V. demonstrated a remarkable upward trend, with expenses surging by over 300% from 2014 to 2022. Notably, 2022 marked a pivotal year for Pharming, surpassing MannKind's expenses by 44%. This shift underscores the dynamic nature of financial strategies within the pharmaceutical sector. As companies navigate the complexities of the market, understanding these financial patterns offers valuable insights into their operational priorities and strategic directions.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Breaking Down SG&A Expenses: Pharming Group N.V. vs ACADIA Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared